Payment overview · 2025
General Payments
$1,018.36
64 reported records · 17 companies
Healthcare provider profile · identity verified
Mindy Dawn Thompson, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · LANDRUM, SC · NPI 1538540745
Verified facts
What the public records show
CMS Open Payments records show Mindy Dawn Thompson, NP received $1,018.36 in general payments during 2025 across 64 reported records.
PFIZER INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $165.90 | 16.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $157.45 | 15.5% | 13 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $143.88 | 14.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $141.71 | 13.9% | 11 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $83.27 | 8.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $58.53 | 5.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $41.02 | 4.0% | 2 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $39.13 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.44 | 3.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $28.38 | 2.8% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $21.29 | 2.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.53 | 2.0% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $19.32 | 1.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.70 | 1.7% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $16.70 | 1.6% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.36 | 1.4% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.75 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,018.36 | 64 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $165.90 | 10 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $143.88 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $141.71 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $128.29 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $116.17 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $94.07 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $68.26 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.38 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.38 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $49.73 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $44.59 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $41.02 | 2 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $39.13 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $35.44 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.38 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $21.29 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.70 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.01 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $14.36 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 112 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 96 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 78 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
78 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
96 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
112 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 467 | 104 |
| Lisinopril | Lisinopril | 387 | 107 |
| Atorvastatin Calcium | Atorvastatin Calcium | 337 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 282 | 79 |
| Pantoprazole Sodium | Pantoprazole Sodium | 257 | 72 |
| Omeprazole | Omeprazole | 250 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 244 | 72 |
| Metformin Hcl | Metformin Hcl | 227 | 60 |
| Lorazepam | Lorazepam | 204 | 38 |
| Losartan Potassium | Losartan Potassium | 199 | 49 |
| Gabapentin | Gabapentin | 198 | 53 |
| Trazodone Hcl | Trazodone Hcl | 197 | 43 |
| Sertraline Hcl | Sertraline Hcl | 172 | 37 |
| Prednisone | Prednisone | 171 | 133 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 44 |
| Metoprolol Succinate | Metoprolol Succinate | 152 | 31 |
| Furosemide | Furosemide | 150 | 48 |
| Simvastatin | Simvastatin | 136 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 134 | 37 |
| Montelukast Sodium | Montelukast Sodium | 134 | 40 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 28 |
| Pregabalin | Pregabalin | 123 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 23 |
| Eliquis | Apixaban | 112 | 25 |
| Tramadol Hcl | Tramadol Hcl | 112 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 111 | 34 |
| Glipizide Er | Glipizide | 108 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 21 |
| Alprazolam | Alprazolam | 102 | 13 |
| Azithromycin | Azithromycin | 97 | 84 |
| Ozempic | Semaglutide | 96 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 96 | 21 |
| Carvedilol | Carvedilol | 93 | 24 |
| Buspirone Hcl | Buspirone Hcl | 90 | 17 |
| Potassium Chloride | Potassium Chloride | 90 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 74 |
| Glimepiride | Glimepiride | 88 | 15 |
| Clonazepam | Clonazepam | 83 | 12 |
| Diazepam | Diazepam | 79 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 17 |
| Famotidine | Famotidine | 73 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 70 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 25 |
| Meloxicam | Meloxicam | 63 | 19 |
| Alendronate Sodium | Alendronate Sodium | 62 | 13 |
| Spironolactone | Spironolactone | 61 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 56 | 34 |
| Glipizide | Glipizide | 55 | 12 |
| Nystatin | Nystatin | 51 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 49 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 46 | 16 |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | suppressed |
| Ondansetron Odt | Ondansetron | 44 | 31 |
| Propranolol Hcl Er | Propranolol Hcl | 44 | suppressed |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Ezetimibe | Ezetimibe | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Memantine Hcl | Memantine Hcl | 39 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 18 |
| Synthroid | Levothyroxine Sodium | 35 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 25 |
| Amoxicillin | Amoxicillin | 33 | 24 |
| Fluconazole | Fluconazole | 32 | 26 |
| Allopurinol | Allopurinol | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Estradiol | Estradiol | 30 | 18 |
| Cephalexin | Cephalexin | 29 | 28 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Atenolol | Atenolol | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 25 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Celecoxib | Celecoxib | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 13 |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Mirtazapine | Mirtazapine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 17 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | 12 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,018.36 · 64 records | PFIZER INC. | AIRSUPRA, BREZTRI, CAPLYTA, CAPVAXIVE, ELIQUIS, ENFLONSIA, EVENITY, GARDASIL 9, INSPIRE, JARDIANCE, KISUNLA, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, WATCHMAN Access System, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error